Literature DB >> 19104374

Medications in pregnancy and lactation: part 1. Teratology.

Catalin S Buhimschi1, Carl P Weiner.   

Abstract

One of the least-developed areas of clinical pharmacology and drug research is the use of medication during pregnancy and lactation. This article is the first in a two-part series designed to familiarize physicians with many aspects of the drugs they commonly prescribe for pregnant and breast-feeding women. Almost every pregnant woman is exposed to some type of medication during pregnancy. Although the majority of pregnant and breast-feeding women consume clinically indicated or over-the-counter drug preparation regularly, only few medications have specifically been tested for safety and efficacy during pregnancy. There is scant information on the effect of common pregnancy complications on drug clearance and efficacy. Often, the safety of a drug for mothers, their fetuses, and nursing infants cannot be determined until it has been widely used. Absent this crucial information, many women are either refused medically important agents or experience potentially harmful delays in receiving drug treatment. Conversely, many drugs deemed "safe" are prescribed despite evidence of possible teratogenicity. Novel research and diagnostic applications evolving from the opportunities presented by the advances in genomics and proteomics are now beginning to affect clinical diagnosis, vaccine development, drug discovery, and unique therapies in a modern diagnostic-therapeutic framework-part of the new scientific field of theranostics. This review critically explores a number of recently raised issues in regard to the use of several classes of medications during gestation and seeks to provide a general and concise resource on drugs commonly used during pregnancy and lactation. It also seeks to make clinicians more aware of the controversies surrounding some drugs in an effort to encourage safer prescribing practices through consultation with a maternal-fetal medicine specialist and through references and Web sites that list up-to-date information.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19104374     DOI: 10.1097/AOG.0b013e31818d6788

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  17 in total

1.  Assessment of foetal risk associated with 93 non-US-FDA approved medications during pregnancy.

Authors:  Ahmed H Al-Jedai; Sakra S Balhareth; Roaa A Algain
Journal:  Saudi Pharm J       Date:  2012-05-19       Impact factor: 4.330

2.  Evaluating medication use in pregnancy and lactation: what every pharmacist should know.

Authors:  Betsy Walters Burkey; Amy P Holmes
Journal:  J Pediatr Pharmacol Ther       Date:  2013-07

3.  Identifying associations between maternal medication use and birth defects using a case-population approach: an exploratory study on signal detection.

Authors:  Linda de Jonge; Priscilla A Zetstra-van der Woude; H Jens Bos; Lolkje T W de Jong-van den Berg; Marian K Bakker
Journal:  Drug Saf       Date:  2013-11       Impact factor: 5.606

Review 4.  Treatment considerations for patients with neuropathic pain and other medical comorbidities.

Authors:  Maija L Haanpää; Geoffrey K Gourlay; Joel L Kent; Christine Miaskowski; Srinivasa N Raja; Kenneth E Schmader; Christopher D Wells
Journal:  Mayo Clin Proc       Date:  2010-03       Impact factor: 7.616

5.  Prenatal exposure to anxiolytics and hypnotics and language competence at 3 years of age.

Authors:  Ingvild Odsbu; Svetlana Skurtveit; Randi Selmer; Christine Roth; Sonia Hernandez-Diaz; Marte Handal
Journal:  Eur J Clin Pharmacol       Date:  2014-12-30       Impact factor: 2.953

Review 6.  Placental control of drug delivery.

Authors:  Sanaalarab Al-Enazy; Shariq Ali; Norah Albekairi; Marwa El-Tawil; Erik Rytting
Journal:  Adv Drug Deliv Rev       Date:  2016-08-12       Impact factor: 15.470

7.  Providing contraception for women taking potentially teratogenic medications: a survey of internal medicine physicians' knowledge, attitudes and barriers.

Authors:  David L Eisenberg; Catherine Stika; Ami Desai; David Baker; Kathleen J Yost
Journal:  J Gen Intern Med       Date:  2010-01-20       Impact factor: 5.128

8.  Pregnancy-associated breast cancer.

Authors:  Erin A Keyser; Barton C Staat; Merlin B Fausett; Andrea D Shields
Journal:  Rev Obstet Gynecol       Date:  2012

9.  Pregnancy outcome of 149 pregnancies in women with epilepsy: Experience from a tertiary care hospital.

Authors:  Ozhan Ozdemir; Mustafa Erkan Sari; Aslihan Kurt; Vefa Selimova Sakar; Cemal Resat Atalay
Journal:  Interv Med Appl Sci       Date:  2015-09-28

10.  Epilepsy drugs and effects on fetal development: Potential mechanisms.

Authors:  Leila Etemad; Mohammad Moshiri; Seyed Adel Moallem
Journal:  J Res Med Sci       Date:  2012-09       Impact factor: 1.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.